Rapid And Robust Preclinical And Clinical Development Of CAR T-Cell Therapies

A growing mid-sized biotech company focused on developing cutting-edge autologous and allogeneic CAR T-cell therapies partnered with Labcorp to advance several ambitious programs targeting solid tumors and hematologic malignancies. The collaboration aimed to support the sponsor in identifying promising lead assets, facilitating a smooth investigational new drug (IND) submission process, and conducting Phase I/II dosing studies—all while adhering to an aggressive development timeline.

Additionally, the sponsor sought to upgrade their operational processes by replacing a manual, spreadsheet-based system used to track patient recruitment and site performance. They required a more sophisticated technology solution that offered real-time data capabilities, enabling improved efficiency and decision-making throughout the clinical trial process.

This multifaceted project demanded seamless coordination across multiple Labcorp business units, leveraging expertise in preclinical pharmacology, toxicology, clinical development, and laboratory services. By integrating these capabilities, Labcorp provided a comprehensive and streamlined approach to accelerate the sponsor’s therapeutic programs and support their overarching mission of advancing transformative CAR T therapies.